Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:BBIO NASDAQ:LEGN NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$14.64+2.1%$14.04$7.86▼$17.75$1.74B1.772.14 million shs772,023 shsBBIOBridgeBio Pharma$45.88-0.1%$39.79$21.72▼$48.68$8.71B1.152.55 million shs1.13 million shsLEGNLegend Biotech$43.84+3.8%$33.81$27.34▼$60.87$8.05B0.191.37 million shs755,068 shsTGTXTG Therapeutics$37.51+0.2%$36.41$16.65▼$46.48$5.96B1.912.84 million shs753,598 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-2.25%-9.81%+3.76%+3.69%+47.08%BBIOBridgeBio Pharma-1.31%-3.75%+9.99%+34.29%+75.26%LEGNLegend Biotech+1.54%+7.07%+24.21%+22.48%-28.11%TGTXTG Therapeutics-1.29%-3.85%+3.89%-1.50%+78.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.2183 of 5 stars3.41.00.00.02.91.70.6BBIOBridgeBio Pharma4.6071 of 5 stars4.51.00.03.92.93.30.6LEGNLegend Biotech3.7138 of 5 stars4.53.00.00.03.41.70.6TGTXTG Therapeutics3.7331 of 5 stars2.40.00.03.53.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8028.46% UpsideBBIOBridgeBio Pharma 3.00Buy$61.5034.06% UpsideLEGNLegend Biotech 2.91Moderate Buy$73.3367.27% UpsideTGTXTG Therapeutics 2.80Moderate Buy$43.8016.78% UpsideCurrent Analyst Ratings BreakdownLatest ARQT, BBIO, TGTX, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.007/9/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.007/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/2/2025LEGNLegend BiotechUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00 ➝ $54.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M8.88N/AN/A$1.35 per share10.84BBIOBridgeBio Pharma$221.90M39.26N/AN/A($7.71) per share-5.95LEGNLegend Biotech$627.24M12.84N/AN/A$5.70 per share7.69TGTXTG Therapeutics$386.39M15.41$0.12 per share316.02$1.43 per share26.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24156.3137.51N/A10.13%18.88%7.05%8/5/2025 (Estimated)Latest ARQT, BBIO, TGTX, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ARQTArcutis Biotherapeutics-$0.19N/AN/AN/A$72.70 millionN/A8/8/2025Q2 2025LEGNLegend Biotech-$0.18N/AN/AN/A$237.49 millionN/A8/7/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/AN/AN/A8/5/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.753.553.37BBIOBridgeBio PharmaN/A4.574.54LEGNLegend Biotech0.305.205.07TGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABBIOBridgeBio Pharma99.85%LEGNLegend Biotech70.89%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BBIOBridgeBio Pharma18.20%LEGNLegend Biotech0.02%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableARQT, BBIO, TGTX, and LEGN HeadlinesRecent News About These CompaniesIFP Advisors Inc Has $7.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 20 at 7:46 AM | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.July 18, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18, 2025 | marketbeat.comEdgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18, 2025 | marketbeat.comSigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 17, 2025 | marketbeat.comBank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 15, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs GroupJuly 13, 2025 | americanbankingnews.comTG Therapeutics (TGTX) Gets a Hold from Goldman SachsJuly 12, 2025 | theglobeandmail.comBanque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)July 11, 2025 | marketbeat.comTG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90July 10, 2025 | msn.comTG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite RatingJuly 10, 2025 | msn.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 10, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLCJuly 9, 2025 | marketbeat.comAxsome Therapeutics Sees Relative Strength Rating Climb To 79July 8, 2025 | msn.comPenserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comNew York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 7, 2025 | marketbeat.comBraun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comJim Cramer on TG Therapeutics: “You Should Buy the Stock”July 2, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARQT, BBIO, TGTX, and LEGN Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$14.64 +0.30 (+2.06%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.BridgeBio Pharma NASDAQ:BBIO$45.88 -0.02 (-0.05%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Legend Biotech NASDAQ:LEGN$43.84 +1.61 (+3.81%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.TG Therapeutics NASDAQ:TGTX$37.51 +0.09 (+0.23%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
